Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW685698X & GW642444M · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| arm 1 | EXPERIMENTAL | study drug |
| Name | Type | Description |
|---|---|---|
| GW685698X & GW642444M | DRUG | study drug |
Inclusion criteria: * Healthy adults aged between 18 and 60 years. * Male subjects or female subjects of non child bearing potential. * Body weight at least 50 kg and BMI within the range of 19-31 kg/m2 inclusive. * No significant abnormality from ECG at screening. * FEV1 at least 90% predicted and...
Top 15 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 5 | PHASE3 | Trelegy Ellipta, Depemokimab, GSK5784283, Ventolin |
| Sanofi SA Sponsored ADR | SNY | 7 | PHASE3 | Dupilumab, Amlitelimab, Lunsekimig |
| AstraZeneca PLC | AZN | 26 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07275315 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
GW685698X & GW642444M is an investigational small molecule combination being developed for asthma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The combination is being studied for its potential use in treating asthma, though it remains in early-stage clinical trials.
GW685698X & GW642444M is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK. The company is conducting clinical research on this combination therapy for asthma, with the drug currently in Phase 1 development.
GW685698X & GW642444M is in Phase 1 clinical development. It is an investigational drug and has not been approved for use. The Phase 1 trial has been completed, and the drug remains in early-stage clinical testing for asthma.
GW685698X & GW642444M has one completed clinical trial, registered as NCT00538057. This Phase 1 study compared the two respiratory drugs when used in combination and separately from a novel inhaler device in healthy subjects. The trial enrolled 16 participants in Australia and was completed.